Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simplified Treat and Extend Ranibizumab for Wet AMD
NCT02328209Unknown
- Sponsor
- Mie University
- Start
- Jun 2014
- Primary completion
- Dec 2016
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of ranibizumab in exudative age-related macular degeneration, sponsored by Mie University. Primary endpoint: Change from baseline best corrected visual acuity at 24 months. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT02328209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02328209.